Vaccinations for Chronic Lung Disease
Patients with chronic lung disease should receive annual influenza vaccination, pneumococcal vaccination (preferably with newer conjugate vaccines PCV21, PCV20, or PCV15 followed by PPSV23), and COVID-19 vaccination as core immunizations, with strong consideration for RSV, pertussis, and varicella-zoster vaccines. 1, 2
Core Recommended Vaccinations
Influenza Vaccine
- Administer annually to prevent acute exacerbations 1
- This is a Grade 1B recommendation with moderate evidence specifically for preventing COPD exacerbations
- High-dose formulations show superior efficacy in at-risk populations, particularly during years of poor strain matching 3
Pneumococcal Vaccination
The landscape has evolved significantly with newer conjugate vaccines:
For adults 19-64 years with chronic lung disease who are vaccine-naive or received only PCV7:
- Give a single dose of PCV21, PCV20, or PCV15 2
- If PCV15 is used, follow with PPSV23 ≥1 year later
- If PCV21 or PCV20 is used, the series is complete
For those who previously received only PPSV23:
- Give PCV21, PCV20, or PCV15 ≥1 year after the last PPSV23 dose 2
Important caveat: In western U.S. regions (Alaska, Colorado, Navajo Nation, New Mexico, Oregon) where serotype 4 causes ≥30% of invasive pneumococcal disease, consider PCV20 over PCV21, as PCV21 lacks serotype 4 coverage 2
The 2015 CHEST guideline recommended PPSV23 as Grade 2C (weak evidence for exacerbation prevention specifically), but emphasized its value for overall pneumococcal disease prevention 1. The 2024 ACIP recommendations now prioritize conjugate vaccines for superior immunogenicity 2.
COVID-19 Vaccination
- Administer variant-adjusted vaccines per current recommendations 3, 4
- Despite decreased mortality from newer variants, chronic lung disease patients remain at elevated risk for exacerbations without vaccination 3
Additional Strongly Recommended Vaccinations
Respiratory Syncytial Virus (RSV)
- Increasingly recommended in international guidelines for chronic respiratory patients 5, 6, 3, 4
- New RSV vaccines are entering markets and show promise in this vulnerable population 6, 3
- Particularly important for older adults and those on immunosuppressive therapy 7
Varicella-Zoster Virus (VZV)
- Recommended for chronic lung disease patients 5, 6, 3, 8
- Subunit vaccines demonstrate long duration of protection 3
- Reduces reactivation rates significantly 6
Pertussis (Tdap)
- Recommended to reduce infection rates 5, 6, 3, 4, 8
- Key limitation: Rapid waning of effectiveness limits long-term protection 6, 3
- Consider periodic boosting, though optimal intervals remain undefined
Special Considerations
For Immunosuppressed Patients
- Hepatitis B vaccination should be considered for those on immunosuppressive therapies 7
- Haemophilus influenzae type b vaccination may provide additional protection 7
Timing and Sequencing
- Space pneumococcal vaccines appropriately (≥1 year between different vaccine types) 2
- Review vaccination status again at age 65 for any needed updates 2
Critical Implementation Gap
Vaccination rates remain unacceptably low despite strong evidence—only 10% of Swiss adults ≥65 years received pneumococcal vaccination in 2020 3. Patient education combined with healthcare provider involvement shows statistically significant improvement in uptake 9.
Algorithmic Approach
- Check vaccination history for all chronic lung disease patients
- Administer immediately if not current: Influenza (annually), COVID-19 (per current schedule)
- Assess pneumococcal status: Use 2024 ACIP algorithm based on prior vaccines 2; default to PCV20 in western U.S., PCV21 elsewhere
- Add RSV vaccine if available, especially age ≥60 or immunosuppressed
- Ensure VZV and Tdap are up to date
- Document and set reminders for annual influenza and periodic boosters